These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 33655751)

  • 1. Biostructural Models for the Binding of Nucleoside Analogs to SARS-CoV-2 RNA-Dependent RNA Polymerase.
    Prussia AJ; Chennamadhavuni S
    J Chem Inf Model; 2021 Mar; 61(3):1402-1411. PubMed ID: 33655751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity.
    Tsuji M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyanorona-20: The first potent anti-SARS-CoV-2 agent.
    Rabie AM
    Int Immunopharmacol; 2021 Sep; 98():107831. PubMed ID: 34247016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) with synthetic/designer unnatural nucleoside analogs: an in silico study.
    Bag SS; Sinha S; Dutta S; Baishya HJ; Paul S
    J Mol Model; 2023 Nov; 29(12):366. PubMed ID: 37950101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying Small-Molecule Inhibitors of SARS-CoV-2 RNA-Dependent RNA Polymerase by Establishing a Fluorometric Assay.
    Bai X; Sun H; Wu S; Li Y; Wang L; Hong B
    Front Immunol; 2022; 13():844749. PubMed ID: 35464436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA-dependent RNA polymerase of SARS-CoV-2 as a therapeutic target.
    Wang Y; Anirudhan V; Du R; Cui Q; Rong L
    J Med Virol; 2021 Jan; 93(1):300-310. PubMed ID: 32633831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase inhibitor, inhibits SARS-CoV-2 variants of concern and exerts synergistic antiviral activity in combination with remdesivir.
    Tang W-F; Chang Y-H; Lin C-C; Jheng J-R; Hsieh C-F; Chin Y-F; Chang T-Y; Lee J-C; Liang P-H; Lin C-Y; Lin G-H; Cai J-Y; Chen Y-L; Chen Y-S; Tsai S-K; Liu P-C; Yang C-M; Shadbahr T; Tang J; Hsu Y-L; Huang C-H; Wang L-Y; Chen CC; Kau J-H; Hung Y-J; Lee H-Y; Wang W-C; Tsai H-P; Horng J-T
    Antimicrob Agents Chemother; 2024 Apr; 68(4):e0095623. PubMed ID: 38446062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review on the interaction of nucleoside analogues with SARS-CoV-2 RNA dependent RNA polymerase.
    Khan S; Attar F; Bloukh SH; Sharifi M; Nabi F; Bai Q; Khan RH; Falahati M
    Int J Biol Macromol; 2021 Jun; 181():605-611. PubMed ID: 33766591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational Analysis Reveals Monomethylated Triazolopyrimidine as a Novel Inhibitor of SARS-CoV-2 RNA-Dependent RNA Polymerase (RdRp).
    Karthic A; Kesarwani V; Singh RK; Yadav PK; Chaturvedi N; Chauhan P; Yadav BS; Kushwaha SK
    Molecules; 2022 Jan; 27(3):. PubMed ID: 35164069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites.
    Shannon A; Le NT; Selisko B; Eydoux C; Alvarez K; Guillemot JC; Decroly E; Peersen O; Ferron F; Canard B
    Antiviral Res; 2020 Jun; 178():104793. PubMed ID: 32283108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plant-Derived Natural Non-Nucleoside Analog Inhibitors (NNAIs) against
    Naidu SAG; Mustafa G; Clemens RA; Naidu AS
    J Diet Suppl; 2023; 20(2):254-283. PubMed ID: 34850656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir.
    Yin W; Mao C; Luan X; Shen DD; Shen Q; Su H; Wang X; Zhou F; Zhao W; Gao M; Chang S; Xie YC; Tian G; Jiang HW; Tao SC; Shen J; Jiang Y; Jiang H; Xu Y; Zhang S; Zhang Y; Xu HE
    Science; 2020 Jun; 368(6498):1499-1504. PubMed ID: 32358203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance.
    Grimes SL; Choi YJ; Banerjee A; Small G; Anderson-Daniels J; Gribble J; Pruijssers AJ; Agostini ML; Abu-Shmais A; Lu X; Darst SA; Campbell E; Denison MR
    mBio; 2023 Aug; 14(4):e0106023. PubMed ID: 37338298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase.
    Zhao J; Guo S; Yi D; Li Q; Ma L; Zhang Y; Wang J; Li X; Guo F; Lin R; Liang C; Liu Z; Cen S
    Antiviral Res; 2021 Jun; 190():105078. PubMed ID: 33894278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural Basis of the Potential Binding Mechanism of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase.
    Zhang L; Zhou R
    J Phys Chem B; 2020 Aug; 124(32):6955-6962. PubMed ID: 32521159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
    Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
    Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.
    Elfiky AA
    Life Sci; 2020 Jul; 253():117592. PubMed ID: 32222463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Theaflavin-3'-O-gallate a Black-tea Constituent Blocked SARS CoV-2 RNA dependant RNA Polymerase Active-site with Better Docking Results than Remdesivir.
    Banerjee A; Kanwar M; Maiti S
    Drug Res (Stuttg); 2021 Oct; 71(8):462-472. PubMed ID: 34517419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying non-nucleoside inhibitors of RNA-dependent RNA-polymerase of SARS-CoV-2 through per-residue energy decomposition-based pharmacophore modeling, molecular docking, and molecular dynamics simulation.
    Aziz S; Waqas M; Mohanta TK; Halim SA; Iqbal A; Ali A; Khalid A; Abdalla AN; Khan A; Al-Harrasi A
    J Infect Public Health; 2023 Apr; 16(4):501-519. PubMed ID: 36801630
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Patil SM; Martiz RM; Ramu R; Shirahatti PS; Prakash A; Chandra S J; Ranganatha VL
    J Biomol Struct Dyn; 2022; 40(23):13032-13048. PubMed ID: 34632942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.